CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Perspective Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Perspective Therapeutics Inc
2401 Elliott Avenue, Suite 320
Phone: (509) 375-1202p:509 375-1202 SEATTLE, WA  98121  United States Ticker: ISR ISR

Business Summary
Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Company’s core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Company’s segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Lori A.Woods 61 2/3/2023 6/4/2018
Chief Executive Officer, Director Johan M.Spoor 50 2/3/2023 2/3/2023
Co- Principal Financial Officer, Principal Accounting Officer, Vice President - Finance, Corporate Mark J.Austin 36 8/16/2021 6/24/2017
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Viewpoint Molecular Targeting, Inc. 2500 Crosspark Rd Coralville IA United States

Business Names
Business Name
CATX
Isoray International, LLC
IsoRay Medical, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 88 (As of 4/27/2023)
Outstanding Shares: 585,322,904 (As of 3/6/2024)
Shareholders: 205
Stock Exchange: ASE
Federal Tax Id: 411458152
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024